Jump to content

Adoptive cell transfer: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
No edit summary
Line 40: Line 40:


== Genetic engineering ==
== Genetic engineering ==
Antitumor receptors genetically engineered into normal T cells can be used for therapy. T cells can be redirected by the integration of genes encoding either conventional alpha-beta TCRs or CARs. CARs ([[chimeric antigen receptor|Chimeric Antibody Receptor]]s) were pioneered in the late 1980s and can be constructed by linking the variable regions of the antibody heavy and light chains to intracellular signaling chains such as CD3-zeta, potentially including costimulatory domains encoding [[CD28]] or [[CD137]]. CARs can provide recognition of cell surface components not restricted to [[major histocompatibility complex]]es (MHC). They can be introduced into T cells with high efficiency using [[viral vectors]].<ref name="rr15" /><ref>Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers.Nat Med. 2016 Jan;22(1):26-36. doi: 10.1038/nm.4015.</ref>
Antitumor receptors genetically engineered into normal T cells can be used for therapy. T cells can be redirected by the integration of genes encoding either conventional alpha-beta TCRs or CARs. CARs ([[chimeric antigen receptor|Chimeric Antibody Receptor]]s) were pioneered in the late 1980s and can be constructed by linking the variable regions of the antibody heavy and light chains to intracellular signaling chains such as CD3-zeta, potentially including costimulatory domains encoding [[CD28]] or [[CD137]]. CARs can provide recognition of cell surface components not restricted to [[major histocompatibility complex]]es (MHC). They can be introduced into T cells with high efficiency using [[viral vectors]].<ref name="rr15" /><ref name=pmid26735408/>


==Early stage T cells==
==Early stage T cells==
Improved antitumor responses have been seen in mouse and monkey models using T cells in early differentiation stages (such as naïve or central memory cells). CD8<sup>+</sup> T cells follow a progressive pathway of differentiation from naïve T cells into central and effector memory populations.<ref>JG Crompton, et al. Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape.Cell Mol Immunol. 2016 Jul;13(4):502-13. doi: 10.1038/cmi.2015.32. Epub 2015 Apr 27.</ref> CD8<sup>+</sup> T cells paradoxically lose antitumor power as they acquire the ability to lyse target cells and to produce the [[cytokine]] [[interferon-γ]], qualities otherwise thought to be important for antitumor efficacy.<ref>Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human memory T cell subset with stem cell-like properties. Nat Med. 2011 Sep 18;17(10):1290-7. doi: 10.1038/nm.2446.</ref><ref>Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005 Jun;115(6):1616-26.</ref> Differentiation state is inversely related to proliferation and persistence. Age is negatively correlated with clinical effectiveness. CD8<sup>+</sup> T cells can exist in a stem cell–like state, capable of clonal proliferation. Human T memory stem cells express a gene program that enables them to proliferate extensively and differentiate into other T cell populations.<ref name="rr15" />
Improved antitumor responses have been seen in mouse and monkey models using T cells in early differentiation stages (such as naïve or central memory cells). CD8<sup>+</sup> T cells follow a progressive pathway of differentiation from naïve T cells into central and effector memory populations.<ref>{{cite journal |last1=Crompton |first1=Joseph G. |last2=Narayanan |first2=Manikandan |last3=Cuddapah |first3=Suresh |last4=Roychoudhuri |first4=Rahul |last5=Ji |first5=Yun |last6=Yang |first6=Wenjing |last7=Patel |first7=Shashank J. |last8=Sukumar |first8=Madhusudhanan |last9=Palmer |first9=Douglas C. |last10=Peng |first10=Weiqun |last11=Wang |first11=Ena |last12=Marincola |first12=Francesco M. |last13=Klebanoff |first13=Christopher A. |last14=Zhao |first14=Keji |last15=Tsang |first15=John S. |last16=Gattinoni |first16=Luca |last17=Restifo |first17=Nicholas P. |title=Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape |journal=Cellular and Molecular Immunology |volume=13 |issue=4 |pages=502–13 |year=2016 |pmid=25914936 |pmc=4947817 |doi=10.1038/cmi.2015.32 }}</ref> CD8<sup>+</sup> T cells paradoxically lose antitumor power as they acquire the ability to lyse target cells and to produce the [[cytokine]] [[interferon-γ]], qualities otherwise thought to be important for antitumor efficacy.<ref>{{cite journal |last1=Gattinoni |first1=Luca |last2=Lugli |first2=Enrico |last3=Ji |first3=Yun |last4=Pos |first4=Zoltan |last5=Paulos |first5=Chrystal M |last6=Quigley |first6=Máire F |last7=Almeida |first7=Jorge R |last8=Gostick |first8=Emma |last9=Yu |first9=Zhiya |last10=Carpenito |first10=Carmine |last11=Wang |first11=Ena |last12=Douek |first12=Daniel C |last13=Price |first13=David A |last14=June |first14=Carl H |last15=Marincola |first15=Francesco M |last16=Roederer |first16=Mario |last17=Restifo |first17=Nicholas P |title=A human memory T cell subset with stem cell–like properties |journal=Nature Medicine |volume=17 |issue=10 |pages=1290–7 |year=2011 |pmid=21926977 |pmc=3192229 |doi=10.1038/nm.2446 }}</ref><ref>{{cite journal |last1=Gattinoni |first1=Luca |last2=Klebanoff |first2=Christopher A. |last3=Palmer |first3=Douglas C. |last4=Wrzesinski |first4=Claudia |last5=Kerstann |first5=Keith |last6=Yu |first6=Zhiya |last7=Finkelstein |first7=Steven E. |last8=Theoret |first8=Marc R. |last9=Rosenberg |first9=Steven A. |last10=Restifo |first10=Nicholas P. |title=Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8<sup>+</sup> T cells |journal=The Journal of Clinical Investigation |volume=115 |issue=6 |pages=1616–26 |year=2005 |pmid=15931392 |pmc=1137001 |doi=10.1172/JCI24480 }}</ref> Differentiation state is inversely related to proliferation and persistence. Age is negatively correlated with clinical effectiveness. CD8<sup>+</sup> T cells can exist in a stem cell–like state, capable of clonal proliferation. Human T memory stem cells express a gene program that enables them to proliferate extensively and differentiate into other T cell populations.<ref name="rr15" />


CD4<sup>+</sup> T cells can also promote tumor rejection. CD4<sup>+</sup> T cells enhance CD8<sup>+</sup> T cell function and can directly destroy tumor cells. Evidence suggests that T helper 17 cells can promote sustained antitumor immunity.<ref name="rr15" /><ref>Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011 Dec 23;35(6):972-85. doi: 10.1016/j.immuni.2011.09.019. Epub 2011 Dec 15.</ref><ref>Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP. Tumor-specific Th17-polarized cells eradicate large established melanoma.Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.
CD4<sup>+</sup> T cells can also promote tumor rejection. CD4<sup>+</sup> T cells enhance CD8<sup>+</sup> T cell function and can directly destroy tumor cells. Evidence suggests that T helper 17 cells can promote sustained antitumor immunity.<ref name="rr15" /><ref>{{cite journal |last1=Muranski |first1=Pawel |last2=Borman |first2=Zachary A. |last3=Kerkar |first3=Sid P. |last4=Klebanoff |first4=Christopher A. |last5=Ji |first5=Yun |last6=Sanchez-Perez |first6=Luis |last7=Sukumar |first7=Madhusudhanan |last8=Reger |first8=Robert N. |last9=Yu |first9=Zhiya |last10=Kern |first10=Steven J. |last11=Roychoudhuri |first11=Rahul |last12=Ferreyra |first12=Gabriela A. |last13=Shen |first13=Wei |last14=Durum |first14=Scott K. |last15=Feigenbaum |first15=Lionel |last16=Palmer |first16=Douglas C. |last17=Antony |first17=Paul A. |last18=Chan |first18=Chi-Chao |last19=Laurence |first19=Arian |last20=Danner |first20=Robert L. |last21=Gattinoni |first21=Luca |last22=Restifo |first22=Nicholas P. |title=Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature |journal=Immunity |volume=35 |issue=6 |pages=972–85 |year=2011 |pmid=22177921 |pmc=3246082 |doi=10.1016/j.immuni.2011.09.019 }}</ref><ref>{{cite journal |last1=Muranski |first1=P. |last2=Boni |first2=A. |last3=Antony |first3=P. A. |last4=Cassard |first4=L. |last5=Irvine |first5=K. R. |last6=Kaiser |first6=A. |last7=Paulos |first7=C. M. |last8=Palmer |first8=D. C. |last9=Touloukian |first9=C. E. |last10=Ptak |first10=K. |last11=Gattinoni |first11=L. |last12=Wrzesinski |first12=C. |last13=Hinrichs |first13=C. S. |last14=Kerstann |first14=K. W. |last15=Feigenbaum |first15=L. |last16=Chan |first16=C.-C. |last17=Restifo |first17=N. P. |title=Tumor-specific Th17-polarized cells eradicate large established melanoma |journal=Blood |volume=112 |issue=2 |pages=362–73 |year=2008 |pmid=18354038 |pmc=2442746 |doi=10.1182/blood-2007-11-120998 }}</ref>
</ref>


==Intrinsic checkpoint blockade==
==Intrinsic checkpoint blockade==
Other modes of enhancing immuno-therapy include targeting so-called intrinsic checkpoint blockades. Recently [[CISH]] was found to be induced by T cell receptor ligation (TCR) and negatively regulate it by targeting the critical signaling intermediate PLC-gamma-1 for degradation.<ref>{{cite journal|last1=Palmer|first1=Douglas|title=CISH actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.|journal=J Exp Med|date=Nov 2, 2015|pmid=26527801|doi=10.1084/jem.20150304|volume=212|pages=2095–113}}</ref> The deletion of CISH in effector T cells has been shown to dramatically augment TCR signaling and subsequent effector cytokine release, proliferation and survival. The adoptive transfer of tumor-specific effector T cells knocked out or knocked down for CISH resulted in a significant increase in functional avidity and long-term tumor immunity. Surprisingly there was no changes in activity of Cish's purported target, STAT5. Thus Cish represents a new class of T-cell intrinsic immunologic checkpoints with the potential to radically enhance adoptive immunotherapies for cancer.
Other modes of enhancing immuno-therapy include targeting so-called intrinsic checkpoint blockades. Recently [[CISH]] was found to be induced by T cell receptor ligation (TCR) and negatively regulate it by targeting the critical signaling intermediate PLC-gamma-1 for degradation.<ref>{{cite journal |last1=Palmer |first1=Douglas C. |last2=Guittard |first2=Geoffrey C. |last3=Franco |first3=Zulmarie |last4=Crompton |first4=Joseph G. |last5=Eil |first5=Robert L. |last6=Patel |first6=Shashank J. |last7=Ji |first7=Yun |last8=Van Panhuys |first8=Nicholas |last9=Klebanoff |first9=Christopher A. |last10=Sukumar |first10=Madhusudhanan |last11=Clever |first11=David |last12=Chichura |first12=Anna |last13=Roychoudhuri |first13=Rahul |last14=Varma |first14=Rajat |last15=Wang |first15=Ena |last16=Gattinoni |first16=Luca |last17=Marincola |first17=Francesco M. |last18=Balagopalan |first18=Lakshmi |last19=Samelson |first19=Lawrence E. |last20=Restifo |first20=Nicholas P. |title=Cish actively silences TCR signaling in CD8+T cells to maintain tumor tolerance |journal=The Journal of Experimental Medicine |volume=212 |issue=12 |pages=2095–113 |year=2015 |pmid=26527801 |pmc=4647263 |doi=10.1084/jem.20150304 }}</ref> The deletion of CISH in effector T cells has been shown to dramatically augment TCR signaling and subsequent effector cytokine release, proliferation and survival. The adoptive transfer of tumor-specific effector T cells knocked out or knocked down for CISH resulted in a significant increase in functional avidity and long-term tumor immunity. Surprisingly there was no changes in activity of Cish's purported target, STAT5. Thus Cish represents a new class of T-cell intrinsic immunologic checkpoints with the potential to radically enhance adoptive immunotherapies for cancer.{{fact}}


== Context ==
== Context ==
Neither tumor bulk nor metastasis site affect the likelihood of achieving a complete cancer regression. Of 34 complete responders in two trials, one recurred. Only one patient with complete regression received more than one treatment. Prior treatment with targeted therapy using [[Braf inhibitor]] [[vemurafenib]] ([[Zelboraf]]) did not affect the likelihood that melanoma patients would experience an objective response. Prior failed immunotherapies did not reduce the odds of objective response.
Neither tumor bulk nor metastasis site affect the likelihood of achieving a complete cancer regression. Of 34 complete responders in two trials, one recurred. Only one patient with complete regression received more than one treatment. Prior treatment with targeted therapy using [[Braf inhibitor]] [[vemurafenib]] ([[Zelboraf]]) did not affect the likelihood that melanoma patients would experience an objective response. Prior failed immunotherapies did not reduce the odds of objective response.{{fact}}


== Stem cells ==
== Stem cells ==
An emerging [[treatment modality]] for various diseases is the transfer of [[stem cells]].<ref>Battinoni L, Klebanoff CA, Restifo NP.Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012 Oct;12(10):671-84. doi: 10.1038/nrc3322. Epub 2012 Sep 21. PMID 22996603</ref> Clinically, this approach has been exploited to transfer either immune-promoting or [[tolerogenic therapy|tolerogenic]] cells (often [[lymphocytes]]) to either enhance immunity against [[virus (biology)|viruses]] and [[cancer]]<ref>{{cite journal |vauthors=Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP |title=Adoptive immunotherapy for cancer: building on success |journal=Nature Reviews Immunology |volume=6 |issue=5 |pages=383–93 |date=May 2006 |pmid=16622476 |pmc=1473162 |doi=10.1038/nri1842}}</ref><ref>{{cite journal |author =June CH |title=Adoptive T cell therapy for cancer in the clinic |journal=The Journal of Clinical Investigation |volume=117 |issue=6 |pages=1466–76 |date=June 2007 |pmid=17549249 |pmc=1878537 |doi=10.1172/JCI32446}}</ref><ref>{{cite journal |vauthors=Schmitt TM, Ragnarsson GB, Greenberg PD |title=T Cell Receptor Gene Therapy for Cancer |journal=Human Gene Therapy |volume=20 |issue= 11|pages=1240–8 |date=October 2009 |pmid=19702439 |pmc=2829456 |doi=10.1089/hum.2009.146}}</ref> or to promote tolerance in the setting of [[autoimmune disease]],<ref name="Riley2009">{{cite journal |vauthors=Riley JL, June CH, Blazar BR |title=Human T Regulatory Cells as Therapeutic Agents: Take a Billion or So of These and Call Me in the Morning |journal=Immunity |volume=30 |issue=5 |pages=656–65 |date=May 2009 |pmid=19464988 |doi=10.1016/j.immuni.2009.04.006 |pmc=2742482}}</ref> such as [[Type I diabetes]] or [[rheumatoid arthritis]]. Cells used in adoptive therapy may be genetically modified using [[recombinant DNA]] technology. One example of this in the case of T cell adoptive therapy is the addition of [[chimeric antigen receptor]]s, or CARs, to redirect the specificity of cytotoxic and helper T cells.
An emerging [[treatment modality]] for various diseases is the transfer of [[stem cells]].<ref>Battinoni L, Klebanoff CA, Restifo NP.Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012 Oct;12(10):671-84. doi: 10.1038/nrc3322. Epub 2012 Sep 21. PMID 22996603</ref> Clinically, this approach has been exploited to transfer either immune-promoting or [[tolerogenic therapy|tolerogenic]] cells (often [[lymphocytes]]) to either enhance immunity against [[virus (biology)|viruses]] and [[cancer]]<ref>{{cite journal |vauthors=Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP |title=Adoptive immunotherapy for cancer: building on success |journal=Nature Reviews Immunology |volume=6 |issue=5 |pages=383–93 |date=May 2006 |pmid=16622476 |pmc=1473162 |doi=10.1038/nri1842}}</ref><ref>{{cite journal |author =June CH |title=Adoptive T cell therapy for cancer in the clinic |journal=The Journal of Clinical Investigation |volume=117 |issue=6 |pages=1466–76 |date=June 2007 |pmid=17549249 |pmc=1878537 |doi=10.1172/JCI32446}}</ref><ref>{{cite journal |vauthors=Schmitt TM, Ragnarsson GB, Greenberg PD |title=T Cell Receptor Gene Therapy for Cancer |journal=Human Gene Therapy |volume=20 |issue= 11|pages=1240–8 |date=October 2009 |pmid=19702439 |pmc=2829456 |doi=10.1089/hum.2009.146}}</ref> or to promote tolerance in the setting of [[autoimmune disease]],<ref name="Riley2009">{{cite journal |vauthors=Riley JL, June CH, Blazar BR |title=Human T Regulatory Cells as Therapeutic Agents: Take a Billion or So of These and Call Me in the Morning |journal=Immunity |volume=30 |issue=5 |pages=656–65 |date=May 2009 |pmid=19464988 |doi=10.1016/j.immuni.2009.04.006 |pmc=2742482}}</ref> such as [[Type I diabetes]] or [[rheumatoid arthritis]]. Cells used in adoptive therapy may be genetically modified using [[recombinant DNA]] technology. One example of this in the case of T cell adoptive therapy is the addition of [[chimeric antigen receptor]]s, or CARs, to redirect the specificity of cytotoxic and helper T cells.{{fact}}


== Applications ==
== Applications ==
Line 114: Line 113:


== Solid tumors ==
== Solid tumors ==
The lack of surface antigens that are not found on essential normal tissues may limit the use of CARs on solid tumors.<ref>{{cite journal |last1=Klebanoff |first1=Christopher A |last2=Rosenberg |first2=Steven A |last3=Restifo |first3=Nicholas P |title=Prospects for gene-engineered T cell immunotherapy for solid cancers |journal=Nature Medicine |volume=22 |issue=1 |pages=26–36 |year=2016 |pmid=26735408 |doi=10.1038/nm.4015 }}</ref> Exceptions include [[neuroblastoma]]s express [[GD2]]. Common epithelial solid cancers account for ≈90% of all cancer fatalities. ACT for such cancers is limited by the lack of suitable/exclusive targets. Searches for monoclonal antibodies that can target solid cancers have continued for more than 30 years, with limited success.<ref name="rr15" />
The lack of surface antigens that are not found on essential normal tissues may limit the use of CARs on solid tumors.<ref name=pmid26735408>{{cite journal |last1=Klebanoff |first1=Christopher A |last2=Rosenberg |first2=Steven A |last3=Restifo |first3=Nicholas P |title=Prospects for gene-engineered T cell immunotherapy for solid cancers |journal=Nature Medicine |volume=22 |issue=1 |pages=26–36 |year=2016 |pmid=26735408 |doi=10.1038/nm.4015 }}</ref> Exceptions include [[neuroblastoma]]s express [[GD2]]. Common epithelial solid cancers account for ≈90% of all cancer fatalities. ACT for such cancers is limited by the lack of suitable/exclusive targets. Searches for monoclonal antibodies that can target solid cancers have continued for more than 30 years, with limited success.<ref name="rr15" />


== Safety ==
== Safety ==

Revision as of 12:03, 30 September 2016

Adoptive cell transfer (ACT) is the transfer of cells into a patient.[1] The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system, with the goal of improving immune functionality and characteristics. In cancer immunotherapy, t cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient.

History

In the 1960s, lymphocytes were discovered to be the mediators of allograft rejection in animals. Attempts to use T cells to treat transplanted murine tumors required cultivating and manipulating T cells in culture. Syngeneic lymphocytes were transferred from rodents heavily immunized against the tumor to inhibit growth of small established tumors, becoming the first example of ACT.[2]

Description of T cell growth factor interleukin-2 (IL-2) in 1976 allowed T lymphocytes to be grown in vitro, often without loss of effector functions. High doses of IL-2 could inhibit tumor growth in mice. 1982 studies demonstrated that intravenous immune lymphocytes could treat bulky subcutaneous FBL3 lymphomas. Administration of IL-2 after cell transfer enhanced therapeutic potential.[2]

In 1985 IL-2 administration produced durable tumor regressions in some patients with metastatic melanoma. Lymphocytes infiltrating the stroma of growing, transplantable tumors provided a concentrated source of tumor-infiltrating lymphocytes (TIL) and could stimulate regression of established lung and liver tumors. In 1986 human TILs from resected melanomas were found to contain cells that could recognize autologous tumors. In 1988 autologous TILs were shown to reduce metastatic melanoma tumors.[2] Tumor-derived TILs are generally mixtures of CD8+ and CD4+ T cells with few major contaminating cells.[2]

A 1989 study replaced the T cell’s natural receptor.[3]

Responses were often of short duration and faded days after administration. In 2002, lymphodepletion using a nonmyeloablative chemotherapy regimen administered immediately before TIL transfer increased cancer regression, as well as the persistent oligoclonal repopulation of the host with the transferred lymphocytes. In some patients, the administered antitumor cells represented up to 80% of the CD8+ T cells months after the infusion.[2]

Initially, melanoma was the only cancer that reproducibly yielded useful TIL cultures. In 2006 administration of normal circulating lymphocytes transduced with a retrovirus encoding a T-cell receptor (TCR) that recognized the MART-1 melanoma-melanocyte antigen, mediated tumor regression. In 2010 administration of lymphocytes genetically engineered to express a chimeric antibody receptor (CAR) against B cell antigen CD19 was shown to mediate regression of an advanced B cell lymphoma.[2]

In 2009, a woman given T cells engineered to recognize colon cancer went into respiratory distress and died.

By 2010, doctors had begun experimental treatments for leukemia patients using CD19-targeted T cells with added DNA to stimulate cell division. As of 2015 trials had treated about 350 leukemia and lymphoma patients. Antigen CD19 appears only on B cells, which go awry in lymphoma and leukemia. Loss of B cells can be countered with immunoglobulin.[3]

Startups including Juno Therapeutics exploit the combination of aggressive tumors and FDA willingness to approve potential therapies for such ailments to accelerate approvals for new therapies.[3]

In checkpoint therapy, antibodies bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses, known as immune checkpoint therapy.[3]

As of 2015 the technique had expanded to treat cervical cancer, lymphoma, leukemia, bile duct cancerand neuroblastoma[2] and in 2016, lung cancer, breast cancer, sarcoma and melanoma.[4] In 2016 CD19-specific chimeric antigen receptor (CAR)-modified T cells were used to treat patients with relapsed and refractory CD19+ B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL) harboring rearrangement of the mixed lineage leukemia (MLL) gene with CD19 CAR-T cells.[5]

In 2016, researchers developed a technique that used cancer cells' RNA to produce T cells and an immune response. They encased the RNA in a negatively charged fatty membrane. In vivo, this electrical charge guided the particles towards the patient's dendritic immune cells that specify immune system targets. The dendritic cells produce cancer antigens that in turn induced an expansion of T cells. Since virtually any tumor antigen can be encoded by RNA, the approach may be able to target multiple cancers.[6][7]

Process

In melanoma, a resected melanoma specimen is digested into a single-cell suspension or divided into multiple tumor fragments. The result is individually grown in IL-2. Lymphocytes overgrow. They destroy the tumors in the sample within 2 to 3 weeks. They then produce pure cultures of lymphocytes that can be tested for reactivity against other tumors, in coculture assays. Individual cultures are then expanded in the presence of IL-2 and excess irradiated anti-CD3 antibodies. The latter targets the epsilon subunit within the human CD3 complex of the TCR. 5–6 weeks after resecting the tumor, up to 1011 lymphocytes can be obtained.[2]

Prior to infusion, a lymphodepleting preparative regimen is undergone, typically 60 mg/kg cyclophosphamide for 2 days and 25 mg/m2 fludarabine administered for 5 days. This substantially increases infused cell persistence and the incidence and duration of clinical responses. Then cells and IL-2 at 720,000 IU/kg to tolerance are infused.[2]

Interleukin-21 may play an important role in enhancing the efficacy of T cell based in vitro therapies.

In early trials, preparing engineered T cells cost $75,000 to manufacture cells for each patient.[3]

In 2015 a T cell-loaded biogel was developed that can be injected directly into the tumor. The gel is made from a biodegradable material taken from crustacean shells and loaded with millions rather than billions of cells as required by standard ACT. The loaded gel is injected either directly into the tumor or alongside it, where it takes the shape of a resistant, cohesive structure that serves as a T cell breeding ground. After 2–3 weeks of replication, they are released and attack tumor cells. Interleukin-2 is normally added to the extracted T cells to boost their effectiveness, but in high doses it can have a toxic effect. The reduced number of injected T cells is accompanied by reduced Il-2, thereby reducing side effects. In vitro ests on melanoma and kidney cancer models met expectations.[8][9]

In 2016 Strep-tag II sequences were introduced into synthetic CAR or natural T-cell receptors to serve as a marker for identification, rapid purification, tailoring spacer length for optimal function and selective, antibody-coated, microbead-driven, large-scale expansion. This facilitates cGMP manufacturing of pure populations of engineered T cells and enables in vivo tracking and retrieval of transferred cells for downstream research applications.[10]

Genetic engineering

Antitumor receptors genetically engineered into normal T cells can be used for therapy. T cells can be redirected by the integration of genes encoding either conventional alpha-beta TCRs or CARs. CARs (Chimeric Antibody Receptors) were pioneered in the late 1980s and can be constructed by linking the variable regions of the antibody heavy and light chains to intracellular signaling chains such as CD3-zeta, potentially including costimulatory domains encoding CD28 or CD137. CARs can provide recognition of cell surface components not restricted to major histocompatibility complexes (MHC). They can be introduced into T cells with high efficiency using viral vectors.[2][11]

Early stage T cells

Improved antitumor responses have been seen in mouse and monkey models using T cells in early differentiation stages (such as naïve or central memory cells). CD8+ T cells follow a progressive pathway of differentiation from naïve T cells into central and effector memory populations.[12] CD8+ T cells paradoxically lose antitumor power as they acquire the ability to lyse target cells and to produce the cytokine interferon-γ, qualities otherwise thought to be important for antitumor efficacy.[13][14] Differentiation state is inversely related to proliferation and persistence. Age is negatively correlated with clinical effectiveness. CD8+ T cells can exist in a stem cell–like state, capable of clonal proliferation. Human T memory stem cells express a gene program that enables them to proliferate extensively and differentiate into other T cell populations.[2]

CD4+ T cells can also promote tumor rejection. CD4+ T cells enhance CD8+ T cell function and can directly destroy tumor cells. Evidence suggests that T helper 17 cells can promote sustained antitumor immunity.[2][15][16]

Intrinsic checkpoint blockade

Other modes of enhancing immuno-therapy include targeting so-called intrinsic checkpoint blockades. Recently CISH was found to be induced by T cell receptor ligation (TCR) and negatively regulate it by targeting the critical signaling intermediate PLC-gamma-1 for degradation.[17] The deletion of CISH in effector T cells has been shown to dramatically augment TCR signaling and subsequent effector cytokine release, proliferation and survival. The adoptive transfer of tumor-specific effector T cells knocked out or knocked down for CISH resulted in a significant increase in functional avidity and long-term tumor immunity. Surprisingly there was no changes in activity of Cish's purported target, STAT5. Thus Cish represents a new class of T-cell intrinsic immunologic checkpoints with the potential to radically enhance adoptive immunotherapies for cancer.[citation needed]

Context

Neither tumor bulk nor metastasis site affect the likelihood of achieving a complete cancer regression. Of 34 complete responders in two trials, one recurred. Only one patient with complete regression received more than one treatment. Prior treatment with targeted therapy using Braf inhibitor vemurafenib (Zelboraf) did not affect the likelihood that melanoma patients would experience an objective response. Prior failed immunotherapies did not reduce the odds of objective response.[citation needed]

Stem cells

An emerging treatment modality for various diseases is the transfer of stem cells.[18] Clinically, this approach has been exploited to transfer either immune-promoting or tolerogenic cells (often lymphocytes) to either enhance immunity against viruses and cancer[19][20][21] or to promote tolerance in the setting of autoimmune disease,[22] such as Type I diabetes or rheumatoid arthritis. Cells used in adoptive therapy may be genetically modified using recombinant DNA technology. One example of this in the case of T cell adoptive therapy is the addition of chimeric antigen receptors, or CARs, to redirect the specificity of cytotoxic and helper T cells.[citation needed]

Applications

Cancer

The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL)[23][24][25] or genetically re-directed peripheral blood mononuclear cells[26][27] has been used experimentally to treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies,[28] cervical cancer, lymphoma, leukemia, bile duct cancerand neuroblastoma,[2] lung cancer, breast cancer, sarcoma, melanoma,[4] relapsed and refractory CD19+ B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL) harboring rearrangement of the mixed lineage leukemia (MLL).[5]

Autoimmune disease

The transfer of regulatory T cells has been used to treat Type 1 diabetes and others.[22]

Trial results

Trials began in the 1990s and accelerated beginning in 2010.[2]

Cells Year Cancer histology Molecular target Patients Number of ORs Comments
Tumor-infiltrating lymphocytes* 1998 Melanoma 20 55% Original use TIL ACT
1994 Melanoma 86 34%
2002 Melanoma 13 46% Lymphodepletion before cell transfer
2011 Melanoma 93 56% 20% CR beyond 5 years
2012 Melanoma 31 48%
2012 Melanoma 13 38% Intention to treat: 26% OR rate
2013 Melanoma 57 40% Intention to treat: 29% OR rate
2014 Cervical cancer 9 33% Probably targeting HPV antigens
2014 Bile duct Mutated ERB2 1 Selected to target a somatic mutation
In vitro sensitization 2008 Melanoma NY-ESO-1 9 33% Clones reactive against cancer-testes antigens
2014 Leukemia WT-1 11 Many treated at high risk for relapse
Genetically engineered with CARs 2010 Lymphoma CD19 1 100% First use of anti-CD19 CAR
2011 CLL CD19 3 100% Lentivirus used for transduction
2013 ALL CD19 5 100% Four of five then underwent allo-HSCT
2014 ALL CD19 30 90% CR in 90%
2014 Lymphoma 15 80% Four of seven CR in DLBCL
2014 ALL CD19 16 88% Many moved to allo-HSCT
2014 ALL CD19 21 67% Dose-escalation study
2011 Neuroblastoma GD2 11 27% CR2 CARs into EBV-reactive cells
Genetically engineered with TCRs 2011 Synovial sarcoma NY-ESO-1 6 67% First report targeting nonmelanoma solid tumor
2006 Melanoma MART-1 11 45%

Solid tumors

The lack of surface antigens that are not found on essential normal tissues may limit the use of CARs on solid tumors.[11] Exceptions include neuroblastomas express GD2. Common epithelial solid cancers account for ≈90% of all cancer fatalities. ACT for such cancers is limited by the lack of suitable/exclusive targets. Searches for monoclonal antibodies that can target solid cancers have continued for more than 30 years, with limited success.[2]

Safety

Toxicity

Targeting normal, nonmutated antigenic targets that are expressed on normal tissues, but overexpressed on tumors has led to severe on-target, off-tumor toxicity. Toxicity was encountered in patients who received high-avidity TCRs that recognized either the MART-1 or gp100 melanoma-melanocyte antigens, in mice when targeting melanocyte antigens, in patients with renal cancer using a CAR targeting carbonic anhydrase 9, in patients with metastatic colorectal cancer.[2]

Toxicities can also result when previously unknown cross-reactivities are seen that target normal self-proteins expressed in vital organs. Cancer-testes antigen MAGE-A3 is not known to be expressed in any normal tissues. However, targeting an HLA-A*0201–restricted peptide in MAGE-A3 caused severe damage to gray matter in the brain, because this TCR also recognized a different but related epitope that is expressed at low levels in the brain. CARs are potentially toxic to self-antigens was observed after infusion of CAR T cells specific for ERBB2. Two patients died when treated with an HLA-A1–restricted MAGE-A3–specific TCR whose affinity was enhanced by a site-specific mutagenesis.[2]

Cancer-testis antigens are a family of intracellular proteins that are expressed during fetal development, but little expression in normal adult tissues. More than 100 such molecules are epigenetically up-regulated in from 10 to 80% of cancer types. However, they lack high levels of protein expression. Approximately 10% of common cancers appear to express enough protein to be of interest for antitumor T cells. Low levels of some cancer-testes antigens are expressed on normal tissues, with associated toxicities. The NYESO-1 cancer-testes antigen has been targeted via a human TCR transduced into autologous cells. ORs were seen in 5 of 11 patients with metastatic melanoma and 4 of 6 patients with highly refractory synovial cell sarcoma.[2]

“Suicide switches” let doctors kill engineered T cells given serious problems.[3]

Cytokine release syndrome

Cytokine release syndrome is another side effect and can be a function of therapeutic effectiveness. As the tumor is destroyed, it turns into large quantities of smaller molecules. This effect killed at least seven patients.[3]

B cells

Molecules shared among tumors and nonessential normal organs represent potential ACT targets, despite the related toxicity. For example, the CD19 molecule is expressed on more than 90% of B cell malignancies and on non-plasma B cells at all differentiation stages and has been successfully used to treat patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia. Toxicity against CD19 results in B cell loss in circulation and in bone marrow that can be overcome by periodic immunoglobulin infusions.[2]

Multiple other B cell antigens are being studied as targets, including CD22, CD23, ROR-1 and the immunoglobulin light-chain idiotype expressed by the individual cancer. CARs targeting either CD33 or CD123 have been studied as a therapy for patients with acute myeloid leukemia, though the expression of these molecules on normal precursors can lead to prolonged myeloablation. BCMA is a tumor necrosis factor receptor family protein expressed on mature B cells and plasma cells and can be targeted on multiple myeloma.[2]

References

  1. ^ Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME (2008). "Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy". JOURNAL OF IMMUNOTHERAPY. 31 (8): 742–751. doi:10.1097/CJI.0b013e31818403d5. PMC 2614999. PMID 18779745.
  2. ^ a b c d e f g h i j k l m n o p q r s t Rosenberg, Steven A.; Restifo, Nicholas P. (2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–8. doi:10.1126/science.aaa4967. PMID 25838374.
  3. ^ a b c d e f g Regalado, Antonio (June 18, 2015). "Biotech's Coming Cancer Cure". Technology Review. Retrieved June 2015. {{cite news}}: Check date values in: |accessdate= (help)
  4. ^ a b "Dramatic remissions in blood cancer in immunotherapy treatment trial". www.kurzweilai.net. March 10, 2016. Retrieved 2016-03-13.
  5. ^ a b Gardner, Rebecca; Wu, David; Cherian, Sindhu; Fang, Min; Hanafi, Laïla-Aïcha; Finney, Olivia; Smithers, Hannah; Jensen, Michael C.; Riddell, Stanley R.; Maloney, David G.; Turtle, Cameron J. (2016). "Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy". Blood. 127 (20): 2406–10. doi:10.1182/blood-2015-08-665547. PMID 26907630.
  6. ^ Lavars, Nick (June 1, 2016). "Trained immune cells raise prospect of universal cancer vaccine". www.gizmag.com. Retrieved 2016-06-12.
  7. ^ Kranz, Lena M.; Diken, Mustafa; Haas, Heinrich; Kreiter, Sebastian; Loquai, Carmen; Reuter, Kerstin C.; Meng, Martin; Fritz, Daniel; Vascotto, Fulvia; Hefesha, Hossam; Grunwitz, Christian; Vormehr, Mathias; Hüsemann, Yves; Selmi, Abderraouf; Kuhn, Andreas N.; Buck, Janina; Derhovanessian, Evelyna; Rae, Richard; Attig, Sebastian; Diekmann, Jan; Jabulowsky, Robert A.; Heesch, Sandra; Hassel, Jessica; Langguth, Peter; Grabbe, Stephan; Huber, Christoph; Türeci, Özlem; Sahin, Ugur (2016). "Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy". Nature. 534 (7607): 396–401. doi:10.1038/nature18300.
  8. ^ Lavars, Nick (2015-11-19). "Injectable, intelligent gel targets cancer at the source". www.gizmag.com. Retrieved 2016-02-21.
  9. ^ Monette, Anne; Ceccaldi, Caroline; Assaad, Elias; Lerouge, Sophie; Lapointe, Réjean (2016). "Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies". Biomaterials. 75: 237–49. doi:10.1016/j.biomaterials.2015.10.021. PMID 26513416.
  10. ^ Liu, Lingfeng; Sommermeyer, Daniel; Cabanov, Alexandra; Kosasih, Paula; Hill, Tyler; Riddell, Stanley R (2016). "Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy". Nature Biotechnology. 34 (4): 430–4. doi:10.1038/nbt.3461. PMC 4940167. PMID 26900664.
  11. ^ a b Klebanoff, Christopher A; Rosenberg, Steven A; Restifo, Nicholas P (2016). "Prospects for gene-engineered T cell immunotherapy for solid cancers". Nature Medicine. 22 (1): 26–36. doi:10.1038/nm.4015. PMID 26735408.
  12. ^ Crompton, Joseph G.; Narayanan, Manikandan; Cuddapah, Suresh; Roychoudhuri, Rahul; Ji, Yun; Yang, Wenjing; Patel, Shashank J.; Sukumar, Madhusudhanan; Palmer, Douglas C.; Peng, Weiqun; Wang, Ena; Marincola, Francesco M.; Klebanoff, Christopher A.; Zhao, Keji; Tsang, John S.; Gattinoni, Luca; Restifo, Nicholas P. (2016). "Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape". Cellular and Molecular Immunology. 13 (4): 502–13. doi:10.1038/cmi.2015.32. PMC 4947817. PMID 25914936.
  13. ^ Gattinoni, Luca; Lugli, Enrico; Ji, Yun; Pos, Zoltan; Paulos, Chrystal M; Quigley, Máire F; Almeida, Jorge R; Gostick, Emma; Yu, Zhiya; Carpenito, Carmine; Wang, Ena; Douek, Daniel C; Price, David A; June, Carl H; Marincola, Francesco M; Roederer, Mario; Restifo, Nicholas P (2011). "A human memory T cell subset with stem cell–like properties". Nature Medicine. 17 (10): 1290–7. doi:10.1038/nm.2446. PMC 3192229. PMID 21926977.
  14. ^ Gattinoni, Luca; Klebanoff, Christopher A.; Palmer, Douglas C.; Wrzesinski, Claudia; Kerstann, Keith; Yu, Zhiya; Finkelstein, Steven E.; Theoret, Marc R.; Rosenberg, Steven A.; Restifo, Nicholas P. (2005). "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells". The Journal of Clinical Investigation. 115 (6): 1616–26. doi:10.1172/JCI24480. PMC 1137001. PMID 15931392.
  15. ^ Muranski, Pawel; Borman, Zachary A.; Kerkar, Sid P.; Klebanoff, Christopher A.; Ji, Yun; Sanchez-Perez, Luis; Sukumar, Madhusudhanan; Reger, Robert N.; Yu, Zhiya; Kern, Steven J.; Roychoudhuri, Rahul; Ferreyra, Gabriela A.; Shen, Wei; Durum, Scott K.; Feigenbaum, Lionel; Palmer, Douglas C.; Antony, Paul A.; Chan, Chi-Chao; Laurence, Arian; Danner, Robert L.; Gattinoni, Luca; Restifo, Nicholas P. (2011). "Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature". Immunity. 35 (6): 972–85. doi:10.1016/j.immuni.2011.09.019. PMC 3246082. PMID 22177921. {{cite journal}}: no-break space character in |first10= at position 7 (help); no-break space character in |first12= at position 9 (help); no-break space character in |first14= at position 6 (help); no-break space character in |first16= at position 8 (help); no-break space character in |first17= at position 5 (help); no-break space character in |first20= at position 7 (help); no-break space character in |first22= at position 9 (help); no-break space character in |first2= at position 8 (help); no-break space character in |first3= at position 4 (help); no-break space character in |first4= at position 12 (help); no-break space character in |first8= at position 7 (help)
  16. ^ Muranski, P.; Boni, A.; Antony, P. A.; Cassard, L.; Irvine, K. R.; Kaiser, A.; Paulos, C. M.; Palmer, D. C.; Touloukian, C. E.; Ptak, K.; Gattinoni, L.; Wrzesinski, C.; Hinrichs, C. S.; Kerstann, K. W.; Feigenbaum, L.; Chan, C.-C.; Restifo, N. P. (2008). "Tumor-specific Th17-polarized cells eradicate large established melanoma". Blood. 112 (2): 362–73. doi:10.1182/blood-2007-11-120998. PMC 2442746. PMID 18354038.
  17. ^ Palmer, Douglas C.; Guittard, Geoffrey C.; Franco, Zulmarie; Crompton, Joseph G.; Eil, Robert L.; Patel, Shashank J.; Ji, Yun; Van Panhuys, Nicholas; Klebanoff, Christopher A.; Sukumar, Madhusudhanan; Clever, David; Chichura, Anna; Roychoudhuri, Rahul; Varma, Rajat; Wang, Ena; Gattinoni, Luca; Marincola, Francesco M.; Balagopalan, Lakshmi; Samelson, Lawrence E.; Restifo, Nicholas P. (2015). "Cish actively silences TCR signaling in CD8+T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
  18. ^ Battinoni L, Klebanoff CA, Restifo NP.Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012 Oct;12(10):671-84. doi: 10.1038/nrc3322. Epub 2012 Sep 21. PMID 22996603
  19. ^ Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (May 2006). "Adoptive immunotherapy for cancer: building on success". Nature Reviews Immunology. 6 (5): 383–93. doi:10.1038/nri1842. PMC 1473162. PMID 16622476.
  20. ^ June CH (June 2007). "Adoptive T cell therapy for cancer in the clinic". The Journal of Clinical Investigation. 117 (6): 1466–76. doi:10.1172/JCI32446. PMC 1878537. PMID 17549249.
  21. ^ Schmitt TM, Ragnarsson GB, Greenberg PD (October 2009). "T Cell Receptor Gene Therapy for Cancer". Human Gene Therapy. 20 (11): 1240–8. doi:10.1089/hum.2009.146. PMC 2829456. PMID 19702439.
  22. ^ a b Riley JL, June CH, Blazar BR (May 2009). "Human T Regulatory Cells as Therapeutic Agents: Take a Billion or So of These and Call Me in the Morning". Immunity. 30 (5): 656–65. doi:10.1016/j.immuni.2009.04.006. PMC 2742482. PMID 19464988.
  23. ^ Besser MJ, Shapira-Frommer R, Treves AJ, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients" Clin. Cancer Res 16 (9) 2646–55. .doi:10.1158/1078-0432.CCR-10-0041 PMID 20406835
  24. ^ Dudley ME, Wunderlich JR, Robbins PF, et al. (October 2002). "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes". Science. 298 (5594): 850–4. doi:10.1126/science.1076514. PMC 1764179. PMID 12242449.
  25. ^ Dudley ME, Wunderlich JR, Yang JC, et al. (April 2005). "Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma". Journal of Clinical Oncology. 23 (10): 2346–57. doi:10.1200/JCO.2005.00.240. PMC 1475951. PMID 15800326.
  26. ^ Johnson LA, Morgan RA, Dudley ME, et al. (July 2009). "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen". Blood. 114 (3): 535–46. doi:10.1182/blood-2009-03-211714. PMC 2929689. PMID 19451549.
  27. ^ Morgan RA, Dudley ME, Wunderlich JR, et al. (October 2006). "Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes". Science. 314 (5796): 126–9. doi:10.1126/science.1129003. PMC 2267026. PMID 16946036.
  28. ^ Kalos M, Levine BL, Porter DL, et al. (August 2011). "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia". Science Translational Medicine. 3 (95): 95ra73. doi:10.1126/scitranslmed.3002842. PMC 3393096. PMID 21832238.